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Summary: The interference of buflomedil with the monoclonal and polyclonal EMIT d. a. u. amphetamine immuno-
assays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false
positive results with the monoclonal EMIT d. a. u. assay, as did urine specimens collected 2 hours after the first oral
dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d. a. u. amphetamine
assay. Urine samples with buflomedil added at concentrations greater than 100 mg/1 gave false positive results with
the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56—400 mg/1) failed to corre-
late to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged
drug, probably interfere in the monoclonal EMIT d. a. u. assay.
Introduction
A urine specimen submitted to toxicological screening
tested positive in the EMIT d. a. u.™ (Syva Company)
monoclonal amphetamine/methamphetamine assay and
negative in the polyclonal amphetamine assay.
The confirmation analyses performed by high perfor-
mance liquid chromatography (HPLC), gas chromato-
graphy (GC), and gas chromatography-mass spectrome-
try (GC-MS) found no evidence for amphetamines, am-
phetamine-like compounds, or other substances structur-
ally unrelated to amphetamines known to produce
positive results with the Syva Company monoclonal
immunoassay test for amphetamines (1—3). Bio-Rad
REMEDi™ (4, 5) analysis suggested the presence of
buflomedil, and GC-MS and HPLC analyses confirmed
the result. Buflomedil hydrochloride, 4-(l-pyrrolidyl)-l-
(2,4,6-trimethoxy-phenyl)-l-butanone hydrochloride, is
a vasodilating agent used in the treatment of cerebrovas-
cular and peripheral arterial diseases. Recommended
therapeutic doses for adults are usually 300-600 mg
orally, or 50-200 mg intravenously, per day.
The present study was undertaken to verify the interfer-
ence of buflomedil with the monoclonal and polyclonal
EMIT d. a. u. amphetamine assays.
Materials and Methods
Study protocol
Urine specimens were collected from 20 patients (7 males and 13
females, ranging from 34 to 91 years of age) receiving orally 600
mg of buflomedil hydrochloride daily. Urine samples from 2 other
patients were collected after 0, 2, 4, 6 hours from the first oral
dose of 600 mg of buflomedil hydrochloride.
Buflomedil was added to drug-free urine specimens to determine
the response of monoclonal and polyclonal EMIT d. a. u. assays for
amphetamines.
Some patients routinely received drugs other than buflomedil.
These drugs were identified and checked for possible interference
by performing amphetamines with immunoassays on drug-free
urine samples spiked with 100 mg/1 of each drug.
Analytical methods
All samples were screened with the Bio-Rad REMEDi Drug Profil-
ing System and by in-house Chromatographie methods (HPLC with
diode array detector and GC with nitrogen/phosphorus detectors),
in order to check for the possible presence of compounds known to
produce a false positive response with amphetamine EMIT d. a. u.
assays. The monoclonal and polyclonal EMIT d. a. u. Syva tests
were performed in a Random 120 analyzer as recommended by the
manufacturer: in particular, the cutoff concentration of the mo-
noclonal assay was 1 mg/1 of D-methamphetamine and the cutoff
concentration of the polyclonal assay was 0.3 mg/1 of Z)-amphet-
amine. HPLC quantitation for buflomedil was performed on all
urine samples using a method including a liquid-liquid extraction
at pH 9 with diethylether/methylene chloride (70 + 30, by vol.)
containing clothiapine as internal standard. Chromatographie con-
ditions were: mobile phase, 2.88 g/1 sodium lauryl sulphate in
water/acetonitrile/glacial acetic acid (45 + 55 + 0.5, by vol.); col-
umn, Lichrosorb Select B Merck; diode array detector wave-
length, 275 nm.
Results and Discussion
All urine specimens of patients treated with buflomedil
yielded a positive response with the monoclonal EMIT
d. a. u. amphetamine assay. Also the urines collected at
2, 4, 6 hours after the first oral dose of buflomedil (2
patients) were positive; the urine samples collected at
time 0 were negative. Conversely, all urine samples ana-
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lyzed using the polyclonal EMIT d. a. u. amphetamine
assay were negative. The toxicological screening per-
formed on all urines excluded the presence of drugs
known to produce false positive with the monoclonal
immunoenzymatic test. The drugs, other than buflo-
medil, tested negative when added to drug-free urine
specimens at 100 mg/1. The urine samples were found
to contain 56—400 mg/1 of buflomedil when analyzed
by the HPLC method.
Figure 1 presents the responses of the monoclonal EMIT
d. a.u. amphetamine assay plotted against the buflo-
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Fig. 1 Scattergram of the results of monoclonal EMIT d. a. u. am-
phetamine immunoassay performed on urine samples from buflo-
medil treated patients (n = 20).
The response of the immunoassay was linearly related
to the concentration of parent drug added to the sample
over the range of 50-400 mg/1 (r = 0.9841). Buflo-
medil-added samples containing 100 mg/1 gave a reac-
tion rate of the cutoff or very close to it, while the real
samples containing buflomedil concentrations signifi-
cantly lower than 100 mg/1 gave rates greater than the
cutoff. These results indicated that one or more buflo-
medil metabolites can also be interfering compounds. In
fact, both on the REMEDi and in-house HPLC chroma-
tograms, the presence of peaks presumably due to me-
tabolites of buflomedil was always observed. Since no
reference standards were available for the metabolites of
buflomedil, their identification was based on the sim-
ilarity of their UV spectra to that of the parent drug.
The data are consistent with the buflomedil excretion
pattern (6-8).
In conclusion, therapeutic doses of buflomedil can cause
false positive results in the EMIT monoclonal amphet-
amine test. In our laboratory we have observed three
cases of acute poisoning due to buflomedil overdosage,
where the urine screenings for amphetamines performed
with monoclonal EMIT d. a. u. Syva gave a positive re-
sult. Such a laboratory finding can generate confusion
for a correct diagnosis, as some important clinical fea-
tures due to buflomedil poisoning (agitation, convul-
sions, tachycardia, respiratory insufficiency) are com-
mon to amphetamine overdosage (6, 9—11).
The confirmation of a positive amphetamine screening
assay is absolutely necessary, nevertheless buflomedil
interference can be easily revealed in urine by Chromato-
graphie methods.
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